Resources

Guidance for licence applicants and holders on assessing whether they are fit and proper to cultivate, produce or manufacture medicinal cannabis.

Guidance for licence applicants and holders on meeting record‑keeping and reporting requirements for medicinal cannabis cultivation, production and manufacture.

Read the 2019 final review of the Narcotic Drugs Act 1967, including recommendations to reduce regulatory burden and support medicinal cannabis industry growth.

Information on how the Office of Drug Control implements cost recovery for regulatory activities.

Read the published submissions received during the 2019 Kava Pilot Phase 1 consultation, which helped inform the development of Australia's Kava Pilot Program.

Review requirement under section 26A of the Narcotic Drugs Act assessing the operation of the 2016 amendments after two years.

Consultation paper on proposed changes to personal kava import limits, seeking feedback on options to ease restrictions for incoming travellers.

Guidance on importing and supplying unregistered medicinal cannabis products, including import requirements, approved supply pathways and record-keeping obligations.

Guidance on importing cannabis seeds and genetic material into Australia, including licence, permit and biosecurity requirements for medicinal cannabis activities.

Information on using cannabis for medicinal and research purposes, including regulations, approvals, and requirements under Australia’s therapeutic framework.

Guidance on testing cannabis and cannabis resin under medicinal cannabis licences, outlining permitted activities, laboratory roles and regulatory requirements.

Application form for a licence to export precursor substances controlled under Regulation 10AB of the Customs (Prohibited Exports) Regulations 1958.

The Customs (Prohibited Exports) Regulations 1958 allow for export of prohibited substances with permission of administering agencies.

Information on how ODC implements cost recovery for regulatory activities (2016).

Regulation supporting licences for cultivating and producing cannabis and cannabis resins for medicinal and scientific purposes under the Narcotic Drugs Act.

The Narcotic Drugs Legislation Amendment Act 2016 protects sensitive law enforcement information used in assessing cannabis licence applications.

The Narcotic Drugs (Licence Charges) Act 2016 enables the Office of Drug Control to accept annual charges from cannabis licence holders.

Independent report examining the potential costs of producing and supplying medicinal cannabis in Australia, including economic modelling and analysis.

Presentation slides from the Commonwealth Medicinal Cannabis Initiative information sessions held in October 2016 on medicinal cannabis reforms and licensing.

Summary of questions and responses from medicinal cannabis consultation sessions on cultivation, manufacturing, licensing and access.

Presentation slides from the Commonwealth Medicinal Cannabis Initiative information and consultation sessions held in July 2016 on medicinal cannabis reforms and regulation.

The Convention on Psychotropic Substances establishes an international control system for psychotropic substances.

The Single Convention aims to combat drug abuse by coordinated international action.

Guidance on international measures to combat drug trafficking, including controls on money laundering and diversion of precursor chemicals.

Application form for a licence to import and/or export narcotic psychotropic and precursor substances.